Last checked at 7 Dec 2023 16:30
Oxford Nanopore Technologies plc
Nanopore Community Meeting Technology Update
7 December 2023
Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, on Wednesday announced an R&D programme delivering a significant jump in platform performance to enable further scientific discovery, in addition to a springboard into clinical markets, as part of a broader technology update at its Nanopore Community Meeting in Houston.
Oxford Nanopore SVP of Product and Programme Management Rosemary Sinclair Dokos and SVP R&D Biologics Lakmal Jayasinghe detailed breakthrough performance in DNA/RNA nanopore sequencing, including new improvements in DNA sequencing accuracy - reaching a record of Q28 (99.8%) in median simplex single pass accuracy - powered by machine learning-guided enzyme engineering and improved models. They also detailed a novel method to overcome errors in homopolymer regions that, when combined with other platform updates, pushed human consensus accuracy up to Q50 and indel F1 accuracy to 99%.
Additional platform updates included significant improvements in direct RNA sequencing to support the emergence of RNA-based therapies as well as numerous research areas of RNA biology, including m6A modified base calling.
As Oxford Nanopore continues to expand its user community in clinical and industrial applied markets, the team also shared the latest on its locked down product platform, Q-line, and announced TurBOT beta access to deliver an optimised sample-to-result product, strengthening its collaboration with Tecan.
A replay of the presentation is available to view on the Oxford Nanopore website at: https://nanoporetech.com/about-us/news/oxford-nanopore-announces-breakthrough-performance-simplex-single-molecule-accuracy
-ENDS-
For further information, please contact:
Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
Teneo (communications adviser to the Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 120 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.
For more information please visit: www.nanoporetech.com
Forward-looking statements
This announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as "aim", "plan", "expect", "intend", "anticipate", "believe", "estimate", "target", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, the COVID-19 pandemic, delays in our receipt of components or our delivery of products to our customers, suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.